Ph 2a multicenter, randomized, open label, two part adaptive design study to evaluate the antiviral effect safety and tolerability of GSK 3810109A, an HIV-1 specific broadly neutralizing human monoclonal antibody in antiretroviral naive HIV-1 adults
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
ViiV Healthcare
Start Date
June 25, 2021
End Date
October 24, 2023
Administered By
Medicine, Infectious Diseases
Awarded By
ViiV Healthcare
Start Date
June 25, 2021
End Date
October 24, 2023